Ovid Therapeutics Inc.

It’s always a pleasure to host the Cacna1a Foundation. CACNA1A Foundation’s mission is to find treatment options and a cure for patients with CACNA1A and have built a network to raise awareness of CACNA1A-linked diseases, which can cause neurodegeneration and other neurological symptoms. While we do not have a program in our pipeline for CACNA1A, we are rooting for them. Lisa Manaster, Sunitha Malepati and Lynn Tusa were in NYC looking for a space to meet, and they are always welcome at Ovid.

Hope to see you again soon!

Presenting our second CCM Warrior, Tymiak! ⚔️

Despite the uncertainty of living with Cerebral Cavernous Malformations (CCM) and not knowing if there will be future complications, Tymiak has learned to navigate through life with resilience and is determined to make a positive impact.

His strength to navigate his CCM journey comes from his faith, his family, and his fellow CCM survivors.

Swipe through to learn more about Tymiak and what makes him a .

Click the link in our bio to join Tymiak and share your story alongside other . Together, we’re stronger. 💪🧠

✨ Event Recap: 20th Anniversary Alliance to Cure Cavernous Malformation International CCM Scientific Meeting ✨

Ovid loved seeing you in Toronto! We had a great time learning more about your stories, taking polaroids for our scrapbook, and having you participate in our CCM Warrior Campaign.

This gathering was an inspiring testament to the dedication and collaboration within the CCM community. We are proud to have been a part of it and remain committed to advancing research and enhancing the quality of life for those affected by this condition.

Thank you again to everyone who made this event possible.

We are thrilled to share that members from Ovid and Graviton are currently attending the 20th Anniversary Alliance to Cure Cavernous Malformation International CCM Scientific Meeting in Toronto!

This prestigious event brings together leading scientists, healthcare professionals, patients, and families to discuss the latest advancements and research in cavernous malformations. We are proud to be a part of this incredible gathering and to contribute to the ongoing efforts in finding effective treatments and improving patient care.

Our mission is to conquer epilepsies and brain conditions with courageous science, but this ambitious goal can only be achieved by keeping patient communities at the center of our efforts. In the latest episode of Patient Worthy's podcast “Wait, How Do You Spell That?”, join our Chief Strategy Officer, Meg Alexander, and Executive Director of the LGS Foundation, Dr. Tracy Dixon-Salazar, as they explore the crucial role of patient advocacy groups in the drug development journey.

The episode delves into how rare disease communities are more than just our stakeholders – they are our thought partners. From helping us determine the best formulation to shaping endpoint goals, their insights are integral to our approach.

Tune in to learn more about how collaborative relationships help companies pave the way for breakthrough treatments that patient communities like Tracy’s truly deserve.

https://waithowdoyouspellthatraredisease.podbean.com/e/epilepsy-and-unmet-need-feat-the-lgs-foundation-and-ovid-therapeutics

Epilepsy and Unmet Need, feat. The LGS Foundation and Ovid Therapeutics | Wait, How Do You Spell That? A Rare Disease Podcast This episode's guests include Dr. Tracy Dixon-Salazar, Executive Director for the Lennox-Gastaut Syndrome (LGS) Foundation, as well as Meg Alexander, Chief Strategy Officer of Ovid Therapeutics. We discuss the treatment landscape for seizure disorders such as LGS and why further research and investm...

Ovid Therapeutics is proud to sponsor and share Cavernoma Alliance UK - CAUK’s latest film series, “Cavernoma Stories.” Please visit the links below to watch Jade and Roxanna’s stories, which bring to light the nuances of living with familial and asymptomatic cavernoma. Our deepest thanks to Jade and Roxanna for their bravery, and to Lucy Gohm, who brings her unique perspective as someone also living with cavernoma, for her work producing the films.

Watch Jade’s Story: https://www.youtube.com/watch?v=yV8llwGZDJE
Watch Roxanna’s Story: https://www.youtube.com/watch?v=X7OEXiRJvnQ

Roxanna's Story - Asymptomatic Cavernoma In 2023 Cavernoma Alliance UK was approached by a filmmaker who has cavernoma, Lucy Gohm. Lucy wanted to help amplify the voices of the cavernoma community, ...

This past weekend, the Alliance to Cure Cavernous Malformation hosted their Annual CCM Family Weekend. It was truly inspiring to see CCM patients and their families come together to share their stories, support each other and celebrate the strength of this incredible community. Thank you to everyone who participated and made this event possible. Your spirit and resilience are what drive us to continue our mission to support and advance the care for those affected by cavernous malformations.

Such valuable findings that shed light on the real experiences of close to 500 patients in Europe with cerebral cavernous malformations (CCM), a neurological condition that affects around 1 in 625 people.

These results are more than just data – they represent the voices of those living with this condition. Understanding these perspectives is essential for guiding our efforts to address the needs of patients, ensuring we focus on what truly matters to them.

Read the full report below to learn more about the symptoms of CCM, the diagnosis journey and the impact this condition has on patients.

What an inspiring afternoon we had at Ovid Therapeutics with Graviton Bioscience! Yesterday, To The Abyss by Rachel Paverman, Kandance Weems Norris, and Connie Sarwatka Lee from the Alliance to Cure Cavernous Malformation, joined us for a special screening of the Eloquent documentary that chronicles their journey of living with CCM.

After the viewing, we had the privilege of diving deeper during a live Q&A panel with those featured in the film. Their courage and insights left us all in awe and more motivated than ever to continue our mission.

On behalf of Ovid and Graviton Bioscience, thank you to the Alliance and to everyone who joined us and made this event unforgettable. Together, we can make a difference!

Watch Ovid’s CEO Jeremy Levin alongside Graviton's Amy Melsaether speak on the exciting potential of ROCK2 inhibition to treat CCM at the Alliance to Cure Cavernous Malformation webinar earlier this May.

Introducing Ovid & Graviton's New ROCK2 Inhibitor for CCM Learn about a ROCK2 Inhibitor medication being developed by Ovid Therapeutics and Graviton Bioscience with the potential to have a significant impact on the ...

Ovid Therapeutics and Graviton Bioscience are thrilled to announce we are working with To The Abyss by Rachel Paverman, a CCM Warrior and incredible advocate for the CCM community. Together, we're embarking on a mission to raise awareness and amplify the voices of those affected by Cerebral Cavernous Malformations. ​

Rachel has demonstrated unwavering dedication to advocating for more good days and wellbeing of the CCM community. Her inspiring efforts and commitment to making a difference have touched the hearts and minds of many, including us.​

We are filled with hope and determination to make a meaningful impact. This is just the beginning. ​

Tune in on Tuesdays, as we work alongside Rachel to showcase her tips on how to navigate the twists and turns that come with having CCM. ​

We recently had an inspiring visit from Christina SanInocencio, founder of the LGS Foundation and chair of the Rare Epilepsy Network (REN). During her talk, Christina shared her story of founding the LGS Foundation and its continued growth into a strong community of support and an important resource for patients and caregivers. She also highlighted the important role REN plays in helping organizations improve the lives of people with rare epilepsies, and we look forward to implementing her insights into our work as we aim to redefine treatment.

We're celebrating 10 years of Ovid! From our humble beginnings to the present day, our commitment to serving patients with and conditions has been unwavering. None of this would have been possible without the dedication and passion of the Ovid team, whose commitment has been the driving force behind our success. We also extend a heartfelt gratitude to our collaborators and supporters who have stood by us every step of the way.

On the rarest day of the year, we joined the world in celebrating . Through RARE Science Inc., we once again hosted a event in our NYC HQ to make one-of-a-kind bears for one-of-a-kind kids impacted by rare diseases. Each of the bears we made will be going to a special and loving home soon!

Today on , we join National Organization for Rare Disorders, Inc. (NORD) and the rare community for with lights of our own at our NYC HQ to raise awareness and show support for those impacted by . On this day, the rare community stands as one to show that rare is not so rare.

We stand with the EveryLife Foundation for Rare Diseases and members of the rare disease community in their efforts for science-driven legislation and policy that advances the equitable development of and access to lifesaving diagnoses and treatments. ‎

EveryLife Foundation Applauds the Introduction of the Creating Hope Reauthorization Act of 2024 – Urges Congress to Act Swiftly - EveryLife Foundation for Rare Diseases The EveryLife Foundation for Rare Diseases applauds the introduction of The Creating Hope Reauthorization Act of 2024, introduced this week in Congress by Representatives McCaul (TX-10), Bilirakis (FL-12), Burgess (TX-26), […]